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Aim: The impact of combinations of anti-cancer drugs and growth factors on tumour cells may differ from the assumed sum of the ef-
fects of each factor separately. Therefore it is important to study the effects of different combinations of various drugs and treat-
ments. Our aim was to study the effects on breast cancer cell proliferation of EGF, TGFβ and 17β-oestradiol, three important 
regulators of breast tumourigenesis, and their respective inhibitors in different combinations. Materials and Methods: We screened 
the effects on proliferation of MCF7 and MDA-MB-231 cells of ninety different combinations of EGF, TGFβ and 17β-oestradiol, 
Iressa, SB431542 and Tamoxifen. Meta-data analysis of available clinical data was performed to validate observed proliferation 
data. Results: In MDA-MB-231 cells, TGFβ1 was found inhibitory when cells were simultaneously treated with EGF and 
17β-oestradiol, with the effect potentiated by addition of all inhibitors combined. In the same cells, Iressa when combined with 
EGF was paradoxically stimulatory. Tamoxifen inhibited MCF7 cells co-treated with EGF or oestrogen, and enhanced the in-
hibitory effect of TGFβ in MDA-MB-231 cells. Meta-analysis of clinical gene expression studies confirmed several of these points, 
showing enhanced TGFβ and EGF expression in Tamoxifen-treated patients to correlate with decreased tumour size and grade 
respectively, and combined TGFβ-EGF expression to decrease the risk of metastasis. Conclusion: Our study shows significant 
differences in proliferation response to drugs and growth factors between MCF7 cells which do not have propensity to form me-
tastases in animal models and MDA-MB-231 cells which may form metastases upon inoculation into animals. Several of these 
differences are unexpected and confirmed by clinical observations.
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Combinatorial treatments are a promising way 
to improve treatment outcomes in cancer with 
decreased resistance development and toxicity. 
 However, cross-talk mechanisms between the drugs 
may produce unexpected toxicities [1]. Combined 
effects of drugs are difficult to predict and may show 
different synergistic or antagonistic effects depending 
on the signalling status of the cells being targeted [2].
In addition, tumour cells are under constant 
influence of physiological regulators which affect 
the tumourigenic properties of the cells and are often 
deregulated in cancer. There have been reported 
a number of studies of various combinations of cell 
regulators. For example, Sutherland et al. reported 
a study of IGF-1, EGF, TGFβ and bFGF effects on the 
proliferation of T-47D cells [3]. Additionally, the proli-
ferative response of human breast cancer cells to poly-
peptide growth factors has been found to be modified 
by oestrogen signalling [4] and ER-EGF signalling 
cross-talk has been implicated in development 
of treatment resistance [5]. These and other similar 
studies have shown that combinations of regulators 
may have unexpected impacts on cell proliferation 
and that these impacts are combination-specific and 
not simply the sums of single treatments. An extensive 
intracellular signalling cross-talk may explain combi-
natorial effects, and signalling differences between 
patients may have an impact on differences in indi-
vidual patient response [6].
Considering cross-talk both between the different 
drugs in a treatment combination and between cell 
signalling pathways in the patient treated, it is neces-
sary to study the impact of drug combinations on cells 
in different signalling states in order to optimise treat-
ment with combinatorial regimens.
EGF, TGFβ and oestrogen are among the most 
potent regulators of human breast epithelial tumouri-
genesis, and deregulation of all these pathways is as-
sociated with different steps in tumour progression. 
Oestrogen signalling drives proliferation in normal 
breast epithelial cells, and deregulation leads first 
to hyperplasia and thereafter to atypical hyperplasia, 
the stage before carcinoma in situ. It also contri butes 
to genetic instability, a hallmark of cancer [7]. EGFR 
deregulation sustains proliferative signalling and 
contributes to development of hormone-independent 
growth in originally oestrogen-dependent cells. 
It also induces angiogenesis and metastasis and 
overexpression correlates with worse prognosis [8]. 
TGFβ1 is a factor inhibiting the growth of tumours 
at an early stage in breast cancer, but deregulation 
in later stages makes TGFβ contribute to development 
of metastasis [9]. Cross-talk mechanisms between 
these pathways have been studied [10–12], but there 
are no screening studies including both drugs and 
growth factors acting on the pathways. Our aim was 
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thus to perform a combinatorial proliferation screening 
of both drugs and ligands acting on these pathways 
in order to find treatment combinations attractive for 
further study, which may aid in personalising cancer 
treatment.
We report a systematic analysis of combinato-
rial treatments with TGFβ1, EGF, 17β-oestradiol, 
Tamoxifen, EGFR kinase inhibitor Iressa and TGFβ 
type I receptor kinase inhibitor SB431542 of MCF7 and 
MDA-MB-231 cells, studying the impact on cell prolif-
eration of 90 different combinations of drug and growth 
factor. There was reported that these cells have dif-
ferent levels of tumourigenic transformation. Notably, 
in the most of studies, MCF7 cells do not have propen-
sity to form metastases in animal models, while MDA-
MB-231 cells may form metastases upon inoculation 
into animals. Despite that there were observations 
that both these cell lines may or may not form tumours 
and metastases, MCF7 cells are considered as cells 
at first steps of transformation, and MDA-MB-231 cells 
are considered as a model of advance transformed 
cells [13–15]. For validation of the  scre ening findings, 
we performed meta-analysis of clinical data. This ap-
proach revealed several unexpected combinatorial 
effects which were found experimentally and validated 
through the meta-analysis, notably that the effects 
of TGFβ are dependent on cross-talk with EGF and 
oestrogen signalling. In conclusion, this study has 
pointed to a number of interesting synergistic and 
antagonistic interactions which may be further studied 
to aid in personalisation of cancer treatment.
MATERIALS AND METHODS
Cells and reagents. MDA-MB-231 and MCF7 cells 
were obtained from ATCC (Mannasas, VA) and cultured 
as recommended. MDA-MB-231 cells form metasta-
ses when injected in animals, while MCF7 may form tu-
mours but do not form metastases. Cells were cultured 
in DMEM medium (Gibco, Carlsbad, CA) with 10% 
FBS and 1% antibiotics (penicillin and streptomycin). 
The cells were monitored for absence of contamina-
tions, e.g. mycoplasma, and for transformation status 
by measuring cells’ colony formation, clonogenicity, 
contact inhibition, proliferation rates and morphology. 
Human recombinant EGF and human recombinant 
TGFβ1 were obtained from Peprotech (Rocky Hill, 
USA), and 17β-oestradiol was obtained from Sigma-Al-
drich (Stockholm, Sweden). Tamoxifen, SB431542 and 
Iressa were obtained from Sigma-Aldrich.
Treatments. In total, 90 combinations were used 
for each cell line. 18 combinations of growth factors 
were used, with TGFβ1 at concentrations of 1 and 
10 ng/ml, EGF at 50 and 100 ng/ml and 17β-oestradiol 
at 10 μM. The growth factors treatments (18 combina-
tions) were combined with the following 5 combina-
tions of drug treatments: none, 10 μM SB431542, 
1 μM Tamoxifen, 10 μM Iressa and SB431542, Tamoxi-
fen and Iressa together at the above concentrations.
MTT assay. Cell proliferation was measured by MTT 
assay (Promega, Madison, WI). The MTT assays were 
performed as described in earlier studies [16]. Cells 
were seeded in 96-well plates at 10 000 cells/well 
in culturing medium. The next day, fresh medium and 
treatments were added. Four wells were used as re-
peats for each condition. Cells were incubated for 48 h, 
whereafter MTT assay was performed and proliferation 
measured as absorbance at 570 nm in a spectropho-
tometer. Representative experiments of three repeats 
are shown in figures. Significance of differences was 
calculated by Student’s t-test.
Clinical correlations. Meta-analysis of clinical 
data has previously been used to study drug interac-
tions [17]. For relevant clinical correlations, we searched 
for microarray studies containing clinical outcome data 
and analysis of TGFβ1 and EGF ligand expression, since 
these ligands were included in our screening.
The study by Lyng et al. [18] comprised 108 ER-
positive patients with invasive ductal or lobular carci-
nomas treated with Tamoxifen. Enhanced TGFβ1 and 
EGF expression were defined by two of three probes for 
each protein having expression values above the total 
patient average.
The study by Ellsworth et al. [19] included twenty 
breast cancer patients with lymph node metastases 
>2.0 mm of different histology and ER/PR/HER2 status 
and studied the difference in gene expression between 
primary tumours and paired metastatic lymph nodes. 
We calculated expression quotas between lymph 
nodes and primary tumour for each patient. Enhanced 
TGFβ1 expression was defined where the quota for 
one of two probes was above the average quota, and 
enhanced EGF expression was defined by the single 
EGF probe quota being above the average quota. Sig-
nificant differences were calculated by Student’s t-test 
in analysis of both studies.
RESULTS
Proliferation screening. We tested the effects 
of combinations of Iressa, SB431542, Tamoxifen, 
TGFβ1, EGF and 17β-oestradiol on cell prolifera-
tion (Fig. 1). The 90 tested conditions are indicated 
in the Material and Methods section. Here we describe 
those conditions which showed unexpected and novel 
responses of cells to treatments.
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Fig. 1. Schematic presentation of the treatments. Links of EGF 
and 17β-oestradiol to growth-promoting, and TGFβ to growth-
inhibitory effects are presented. Effects of Iressa, SB431542 and 
Tamoxifen on EGF, TGFβ and 17β-oestradiol regulated signalling 
are indicated
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The effect of TGFβ1 is dependent on cross-talk with 
the other treatments. MCF7 cells generally showed 
a trend towards inhibition by TGFβ1, while in MDA-
MB-231 cells, an inhibitory effect of TGFβ1 was only 
seen in cells co-treated with EGF and 17β-oestradiol 
(Fig. 2). This shows that an inhibitory effect may 
be enhanced by treatment with two traditional growth 
stimulators. Further support for the importance 
of oestrogen and TGFβ signalling cross-talk is pro-
vided by the fact that MDA-MB-231 cells treated with 
ER antagonist Tamoxifen were inhibited in a TGFβ1-
concentration-dependent manner, while MCF7 cells 
on the other hand were inhibited upon addition of EGF 
or oestrogen regardless of TGFβ1 concentration 
(Fig. 3). Since MDA-MB-231 cells are ER-, this, as well 
as the stimulatory effect seen by Tamoxifen alone, may 
point to Tamoxifen off-ER-target effects.
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Fig. 2. Proliferation of MDA-MB-231 and MCF7 without ad-
dition of drugs shows the combination of EGF, 17β-oestradiol 
and TGFβ1 to inhibit proliferation in MDA-MB-231 but not 
in MCF7 cells. Treatment conditions are annotated. **(p < 0.01) 
is in comparison with untreated cells
While Iressa did inhibit MDA-MB-231 cells, TGFβ1 did 
not have an additional inhibitory effect, but rather blocked 
the stimulatory effect of EGF, showing that the effect 
of TGFβ also depends on EGF signalling (Fig. 4).
Treatment of cells with all three inhibitors — Iressa, 
Tamoxifen and SB431542 — showed the same trends 
in effects on proliferation as untreated cells (see 
Fig. 2), with the difference that EGF + 17β-oestradiol 
treatment inhibited MDA-MB-231 cells regardless 
of TGFβ treatment (Fig. 5), providing further evidence 
that the effect of drugs in combination is not simply 
an addition of the single drug effects, but the result 
of signalling cross-talk.
Meta-analysis of clinical correlations. Through 
meta-analysis of original data reported by Ells-
worth et al. [19], which focused on gene signatures 
predicting metastasis, we found that an increased 
rate of TGFβ1 and EGF ligand co-expression in lymph 
node metastases compared with primary tumours from 
the same patients significantly correlated with a lower 
number of positive lymph nodes (Fig. 6, a), implying 
that in the metastatic process, cells co-expressing 
TGFβ and EGF are less prone to metastasize. While 
the original data did not allow the evaluation of an ad-
ditional impact of oestrogen signalling, the available 
meta-data confirm our observations of the inhibitory 
effects on cell proliferation by TGFβ1 being dependent 
on EGF (see Fig. 2).
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Fig. 3. Proliferation of MDA-MB-231 and MCF7 cells treated 
with 1 μM Tamoxifen shows MDA-MB-231 proliferation to de-
crease in a TGFβ1-dependent manner. MCF7 cells are inhibited 
by 17β-oestradiol and EGF independent of TGFβ1. Treatment 
conditions are annotated. For MCF7, significant differences are 
in comparison to Tamoxifen only (*p < 0.05; **p < 0.01)
Meta-analysis of the study by Lyng et al. [18], com-
prising 108 ER+ patients treated with Tamoxifen, found 
that patients with above average TGFβ1 expression had 
smaller tumours than both patients where TGFβ1 and 
EGF were co-expressed and the total patient average 
(Fig. 6, b), while patients with above average EGF expres-
sion had a lower grade of malignancy (Fig. 6, c). Other 
variations in clinical observations and TGFβ and EGF 
activities were found to be not significant. These data 
support our observations where the proliferation in both 
cell lines was decreased when Tamoxifen was combined 
with TGFβ1 (MDA-MB-231) or EGF (MCF7) (see Fig. 3).
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Fig. 4. Proliferation of MDA-MB-231 and MCF7 cells upon treat-
ment with 10 μM Iressa shows EGF to have a stimulatory effect, 
which is counteracted by addition of TGFβ1, in the presence 
of Iressa in MDA-MB-231 cells. “Untreated control” indicates 
condition with no treatments. Treatment conditions are annotated 
(*p < 0.05, **p < 0.01) 
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Fig. 5. Proliferation of MDA-MB-231 and MCF7 cells exposed 
to 10 μM Iressa, 1 μM Tamoxifen and 10 μM SB431542 shows 
combined application of EGF and 17β-oestradiol to inhibit MDA-
MB-231 cells. Treatment conditions are annotated. “Untreated 
control” indicates condition with no treatments. Significant 
differences *(p < 0.05) and **(p < 0.01) are in comparison with 
cells treated only with the three inhibitors
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Fig. 6. Clinical outcomes of TGFβ and EGF co-expression. 
a) Meta-analysis of data reported by the study by Ells-
worth et al. [19] shows TGFβ1 and EGF co-expression in lymph 
node metastases to correlate with fewer positive lymph nodes. 
b) Meta-analysis of data reported by the study by Lyng et al. [18] 
on Tamoxifen-treated patients shows TGFβ1 expression to cor-
relate with  smaller tumours. Significant differences *(p < 0.05) 
and **(p < 0.01) are in comparison with the group showing 
enhanced TGFβ expression. c) In the study by Lyng et al. [18], 
EGF expression was associated with a lower grade of malignancy. 
**(p < 0.01) and *(p < 0.05) are in comparison with EGF condition
DISCUSSION
It is an accepted fact that combinations of multiple 
cellular regulators may have different impacts as com-
pared to the sum of the same regulators applied indi-
vidually. Thus, it is necessary to study multiple interac-
tions not only between potential drug candidates but 
also the interplay between the drugs and the different 
growth factors whose signalling is deregulated in can-
cer cells. Our study focused on exploring the effects 
on cell proliferation by TGFβ1, EGF, 17β-oestradiol, 
Tamoxifen, Iressa and SB431542. We observed diffe-
rences in response between the ER− MDA-MB-231 and 
ER+ MCF7 cell lines.
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The main novel findings were 1) that TGFβ1 inhibi-
ted proliferation of MDA-MB-231 cells when the cells 
are also treated with EGF and oestrogen, 2) that 
exposure of MDA-MB-231 cells to Tamoxifen, EGF 
and/or 17β-oestradiol promoted the inhibitory effect 
of TGFβ1, while combinations of Tamoxifen, EGF and/
or 17β-oestradiol inhibited MCF7 proliferation irre-
spectively of TGFβ1 addition, 3) that addition of EGF 
to Iressa had a stimulatory effect, which was blocked 
by TGFβ1, in MDA-MB-231 cells, and 4) that co-treat-
ment with Iressa, Tamoxifen and SB431542 showed 
the same general response trend as untreated cells. 
The latter fact implies a cross-inhibition between 
the drugs, further underlining the fact that addition 
of new drugs, proven effective when used alone, 
to existing treatment regimens, may have a negative 
effect. Tamoxifen alone somewhat increased MDA-
MB-231 cell proli feration. Since these cells are ER−, 
this is not completely unexpected. Tamoxifen has 
earlier been observed to increase the proliferation 
of Tamoxifen-resistant breast cancer cells [20].
The correlations between TGFβ and EGF gene ex-
pression and clinical outcomes confirm certain of our 
findings, showing impact on tumour size and grade 
when EGF or TGFβ are combined with Tamoxifen, and 
a reduction in lymph node metastasis upon TGFβ-EGF 
co-expression.
Our findings underline the need for in-depth study 
of drug and growth factor interactions before applica-
tion of any combinatorial regimen in cancer treatment. 
This study particularly highlights the different roles 
of TGFβ in regulating cell proliferation, and how the im-
pact of TGFβ is dependent on cell type and cross-talk 
with EGF and oestrogen signalling.
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